3-甲基-3-苯基哌啶 | 19735-13-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 3-甲基-3-苯基哌啶
• 英文名称: (RS)-3-methyl-3-phenylpiperidine
• 英文别名: 3-methyl-3-phenylpiperidine；3-methyl-3-phenyl-piperidine；3-Methyl-3-phenyl-piperidin；3-Methyl-3-phenylpiperidin
• CAS: 19735-13-8
• 化学式: C₁₂H₁₇N
• mdl: MFCD00087528
• 分子量: 175.274
• InChiKey: JMPNCLOLPRVYKK-UHFFFAOYSA-N

物化性质

• 沸点：
  266.8±19.0 °C(Predicted)
• 密度：
  0.946±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  3-甲基-3-苯基哌啶 在 甲基叔丁基醚 、 palladium 10% on activated carbon 、 氢气 、 硝酸 作用下， 以 甲醇 、 二氯甲烷 为溶剂， -5.0~20.0 ℃ 、379.22 kPa 条件下， 反应 3.17h， 生成 tert-butyl 3-(4-aminophenyl)-3-methylpiperidine-1-carboxylate
  参考文献：
  名称：

  [EN] PHARMACEUTICAL COMPOUNDS
  [FR] COMPOSÉS PHARMACEUTIQUES

  摘要：

  提供了作为Wee-1激酶活性抑制剂有用的化合物。还提供了包含这些化合物的药物组合物以及使用这些化合物治疗癌症的方法和治疗癌症的方法。

  公开号：

  WO2019138227A1

文献信息

• DIAMINE SYNTHESIS VIA CATALYTIC C-H AMINATION OF AZIDES
  申请人：Zhang X. Peter

  公开号：US20120101271A1

  公开（公告）日：2012-04-26

  Selective intramolecular C—H amination via metalloradical activation of azides: synthesis of 1,3-diamines under neutral and nonoxidative conditions. One aspect of the present invention is the synthesis of 1,3-diamines by intramolecular C—H amination of sulfamoyl azides. More specifically, sulfamoyl azides may be selectively aminated via metalloradical activation of azides, preferably with Co(II) porphyrins. In a particularly preferred embodiment, the Co(II) porphyrin is a D 2h -symmetric porphyrin.

  通过金属自由基活化叠氮化合物的选择性分子内C—H胺化：在中性和非氧化条件下合成1,3-二胺。本发明的一个方面是通过叠氮磺酰胺的分子内C—H胺化合成1,3-二胺。更具体地说，叠氮磺酰胺可以通过金属自由基活化叠氮化合物进行选择性胺化，最好使用Co(II)卟啉。在一个特别优选实施例中，Co(II)卟啉是一个D2h对称的卟啉。
• Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by np y5 receptor
  申请人：——

  公开号：US20030225097A1

  公开（公告）日：2003-12-04

  Compounds of formula (I): 1 wherein: X is a group of formula (A) or (B): 2 and R 1 , R 2 , R 3 , R 4 , n, x, y and z are as defined within are described. Processes for their preparation and their use in the treatment of disorders mediated by the neuropeptide Y5 receptor in a warm-blooded animal, such as a human being are also described.

  式(I)的化合物： 其中： X是式(A)或(B)的基团： 而R1、R2、R3、R4、n、x、y和z的定义如所述。 还描述了它们的制备过程以及它们在治疗由神经肽Y5受体介导的疾病中的用途，如在温血动物，如人类中的用途。
• Inhibitors of hepatitis C virus NS3 protease
  申请人：——

  公开号：US20030064962A1

  公开（公告）日：2003-04-03

  The present invention relates generally to a novel class of pyrimidinones of Formula (I): 1 that are useful as serine protease inhibitors, and more particularly as Hepatitis C virus NS3 protease inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of using the same.

  本发明一般涉及一种新型的嘧啶酮类化合物，具有如下式（I）所示的结构，这些化合物可用作丝氨酸蛋白酶抑制剂，更具体地作为丙型肝炎病毒NS3蛋白酶抑制剂。本发明还涉及包含这些化合物的药物组合物以及使用这些药物的方法。
• [EN] 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS<br/>[FR] DÉRIVÉS 1,2,4-TRIAZOLO[4,3-A]PYRIDINE ET LEUR UTILISATION EN TANT QUE MODULATEURS ALLOSTÉRIQUES POSITIFS DES RÉCEPTEURS MGLUR2
  申请人：JANSSEN PHARMACEUTICALS INC

  公开号：WO2012062759A1

  公开（公告）日：2012-05-18

  The present invention relates to novel triazolo[4,3-a]pyridine derivatives of Formula (I) wherein all radicals are as defined in the claims. The compounds according to the invention are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 ("mGluR2"), which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases in which mGluR2 is involved.

  本发明涉及新型Formula (I)的三唑并[4,3-a]吡啶衍生物，其中所有基团如权利要求中所定义。根据本发明的化合物是代谢型谷氨酸受体亚型2（"mGluR2"）的阳性变构调节剂，可用于治疗或预防与谷氨酸功能障碍相关的神经和精神疾病以及mGluR2代谢型受体亚型参与的疾病。本发明还涉及包含这种化合物的药物组合物，用于制备这种化合物和组合物的过程，以及利用这种化合物预防或治疗mGluR2参与的神经和精神疾病和疾病。
• Antiparasitic terpene alkaloids
  申请人：Chubb A. Nathan

  公开号：US20070185101A1

  公开（公告）日：2007-08-09

  The present invention relates to novel terpene alkaloids and their use as antiparasitic agents. The present invention also relates to an antiparasitic agent which comprises a terpene alkaloid compound of this invention as an effective ingredient in an, antiparasitic formulation. More particularly, the present invention relates to derivatives of the terpene alkaloid (1S,2R,4aS,5R,8R,8aR)-2-(acetyloxy)-8a-hydroxy-3,8-dimethyl-5-(1-methylethenyl)-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl (2S,3aR,9bR)-6-chloro-9b-hydroxy-5-methyl-1,2,3,3a,5,9b-hexahydropyrrolo[2,3-c][2,1]benzoxazine-2-carboxylate. Pharmaceutical compositions comprising the same are also disclosed.

  本发明涉及新型萜类生物碱及其作为抗寄生虫剂的用途。本发明还涉及一种抗寄生虫剂，其包含本发明中的萜类生物碱化合物作为抗寄生虫制剂中的有效成分。更具体地，本发明涉及萜类生物碱（1S，2R，4aS，5R，8R，8aR）-2-（乙酰氧基）-8a-羟基-3，8-二甲基-5-（1-甲基乙烯基）-1,2,4a,5,6,7,8,8a-八氢萘-1-基（2S，3aR，9bR）-6-氯-9b-羟基-5-甲基-1,2,3,3a,5,9b-六氢吡咯[2,3-c] [2,1]苯并噁唑-2-羧酸酯的衍生物。还公开了包含该物质的药物组合物。